Neuland Laboratories Intrinsic Value
NEULANDLAB • Healthcare
Current Stock Price
₹12433.00
Primary Intrinsic Value
₹6643.12
Market Cap
₹161.6K Cr
-62.5%
Downside
Median Value
₹4665.28
Value Range
₹2487 - ₹6643
Assessment
Trading Above Calculated Value
Safety Margin
-100.0%
NEULANDLAB Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹6643.12 | ₹5314.50 - ₹7971.74 | -46.6% | EPS: ₹301.96, Sector P/E: 22x |
| Book Value Method | asset | ₹2486.60 | ₹2237.94 - ₹2735.26 | -80.0% | Book Value/Share: ₹1173.08, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹3729.90 | ₹3356.91 - ₹4102.89 | -70.0% | Revenue/Share: ₹1587.69, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹4973.20 | ₹4475.88 - ₹5470.52 | -60.0% | EBITDA: ₹628.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹4973.20 | ₹3978.56 - ₹5967.84 | -60.0% | CF Growth: 13.8%, Discount: 15% |
| PEG Ratio Method | growth | ₹3729.90 | ₹3356.91 - ₹4102.89 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹4665.28 | ₹4198.75 - ₹5131.81 | -62.5% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹6216.50 | ₹5594.85 - ₹6838.15 | -50.0% | ROE: 25.4%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹3729.90 | ₹3356.91 - ₹4102.89 | -70.0% | EPS: ₹301.96, BVPS: ₹1173.08 |
Method Types:
Earnings
Asset
DCF
Growth
Dividend
Conservative
Valuation Comparison Chart
NEULANDLAB Intrinsic Value Analysis
What is the intrinsic value of NEULANDLAB?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Neuland Laboratories (NEULANDLAB) is ₹4665.28 (median value). With the current market price of ₹12433.00, this represents a -62.5% variance from our estimated fair value.
The valuation range spans from ₹2486.60 to ₹6643.12, indicating ₹2486.60 - ₹6643.12.
Is NEULANDLAB undervalued or overvalued?
Based on our multi-method analysis, Neuland Laboratories (NEULANDLAB) appears to be trading above calculated value by approximately 62.5%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 6.03 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 25.4% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 30.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.95x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Neuland Laboratories
Additional stock information and data for NEULANDLAB
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹317 Cr | ₹168 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹261 Cr | ₹186 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹237 Cr | ₹207 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹60 Cr | ₹13 Cr | Positive Free Cash Flow | 7/10 |
| March 2021 | ₹189 Cr | ₹147 Cr | Positive Free Cash Flow | 8/10 |